CN104860919B - Benzimidizole derivatives containing piperidines and its production and use - Google Patents

Benzimidizole derivatives containing piperidines and its production and use Download PDF

Info

Publication number
CN104860919B
CN104860919B CN201510137918.5A CN201510137918A CN104860919B CN 104860919 B CN104860919 B CN 104860919B CN 201510137918 A CN201510137918 A CN 201510137918A CN 104860919 B CN104860919 B CN 104860919B
Authority
CN
China
Prior art keywords
compound
formula
group
pharmaceutically acceptable
structure shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510137918.5A
Other languages
Chinese (zh)
Other versions
CN104860919A (en
Inventor
刘登科
刘颖
刘冰妮
樊梦林
王兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Tiancheng new drug evaluation Co.,Ltd.
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Priority to CN201510137918.5A priority Critical patent/CN104860919B/en
Publication of CN104860919A publication Critical patent/CN104860919A/en
Application granted granted Critical
Publication of CN104860919B publication Critical patent/CN104860919B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to hypoglycemic effect technical field of pharmaceuticals, there is provided there are the benzimidizole derivatives and its pharmaceutically acceptable salt containing piperidines of structure shown in formula I, wherein：R1、R2、R3Definition as used in the description.The invention further relates to the preparation method of above-claimed cpd, and also disclose using the compound or its pharmaceutically acceptable salt as the pharmaceutical composition of active ingredients, and their applications in terms of as hypoglycemic drug.

Description

Benzimidizole derivatives containing piperidines and its production and use
Technical field
The invention belongs to pharmaceutical technology field, more precisely, being to be related to a kind of hypoglycemic compound and its preparation side Method, the pharmaceutical composition containing them and the purposes as hypoglycemic drug.
Background technology
Diabetes (diabetes mellitus, DM) be it is a kind of relative to genetic related endogenous insulin or DKA can occur for the whole body chronic disease of sugar, fat and protein metabolism disorder, severe patient definitely caused by deficiency, Hyperosmolar coma, and easily merge multi-infection.With the extension of the course of disease, its metabolic disorder can cause eye, kidney, nerve, blood vessel and The chronic disease of more tissues such as heart.Current about 2.85 hundred million diabetics in the world, account for the 6.4% of world population, in advance Count to the year two thousand thirty, be up to 4.38 hundred million, and patient is concentrated mainly on the countries in Southeast Asia such as India and China, sugar in Chinese adult The illness rate of patient is urinated already close to 10%.For individual level, diabetes will also than life loss caused by hypertension Seriously, its case fatality rate is only second to angiocardiopathy, malignant tumour, the referred to as lethal cause of disease disease of the 3rd in developed country
With the continuous discovery for the treatment of diabetes novel targets, the mechanism of action of various treatment diabetes medicaments is different, drug effect Also it is not quite similar with toxicity.At present, clinically mainly using the method for a variety of OHAs and insulin intensive treatment To delay diabetes progression.In addition to insulin, sulfonylureas, biguanides, alpha-glucosidase inhibitor, thiazolidinediones, benzoic acid The medicines such as derivative are current clinical conventional treatment diabetes medicaments.The hypoglycemic action fastoperation of these medicines is strong, but in sugar Still there are many vacancies in terms of urinating disease early stage, insulin resistance, complication at present, these medicines of patient's long-term use easily cause not The shortcomings that long-term efficacy can be maintained, also easily cause hypoglycemia, increased weight, produce hepatotoxicity wind agitation and induce hypoglycemia angiocarpy disease The side effects such as disease, there is no protective effect to the islet cells of damage yet.
Therefore, finding more safe and effective novel blood sugar lowing medicine turns into one of focus of researcher research.
The content of the invention
It is an object of the present invention to develop the benzimidizole derivatives containing piperidines of a kind of new structure and its medicinal Salt.
It is another object of the present invention to disclose the preparation sides of benzimidizole derivatives and its pharmaceutical salts containing piperidines Method.
Another object of the present invention is that it is main to disclose using the benzimidizole derivatives containing piperidines and its pharmaceutical salts The pharmaceutical composition of active component.
A further object of the invention is, benzimidizole derivatives and its pharmaceutical salts containing piperidines is disclosed, as drop Application in terms of hypoglycemic medicament, particularly for preparing prevention or treating pancreas function exhaustion, mistake because of caused by hyperglycaemia Purposes in terms of the disease medicaments such as water and rock-soil coupling, nutritional deficiency, resistance decline, impaired renal function, DPN.
Understand that the compounds of this invention has a certain degree of superiority through Preliminary pharmacological test.
In conjunction with the object of the invention, present invention is described in detail.
Present invention relates particularly to the compound of logical structure shown in formula I and its pharmaceutically acceptable salt：
Wherein：
R1For：Hydrogen, fluorine, chlorine, bromine atoms, C1-C4Straight or branched alkyl；
R2For：Hydrogen, ethyoxyl alkyl；
R3For：(a)Wherein R4, R5It is at the same time or separately hydrogen, C1-C4Alkyl, halogen, nitro, cyano group, C1- C4Alkoxy；
(b)Wherein X is O or S；R6, R7It is at the same time or separately hydrogen, C1-C4Alkyl, halogen, nitro, cyano group, C1- C4Alkoxy.
Compound and its pharmaceutically acceptable salt of the present invention with logical structure shown in formula I are preferably：
Wherein：
R1For：Hydrogen, fluorine, chlorine, bromine atoms, methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, the tert-butyl group；
R2For：Hydrogen, ethyoxyl alkyl；
R3For：(a)Wherein R4, R5At the same time or separately for hydrogen, methyl, ethyl, propyl group, isopropyl, butyl, Isobutyl group, the tert-butyl group, fluorine, chlorine, bromine, nitro, cyano group, methoxyl group, ethyoxyl, propoxyl group, isopropoxy, butoxy, tertiary fourth oxygen Base；
(b)Wherein X is O or S；R6, R7At the same time or separately for hydrogen, methyl, ethyl, propyl group, isopropyl, butyl, Isobutyl group, the tert-butyl group, fluorine, chlorine, bromine, nitro, cyano group, methoxyl group, ethyoxyl, propoxyl group, isopropoxy, butoxy, tertiary fourth oxygen Base.
The compound or its pharmaceutically acceptable salt with structure shown in formula I of the present invention, which part compound are：
I -1 2- (1- tosylpiperidin -4- bases) -1H- benzimidazoles
I -2 1- (2- ethoxyethyl groups) -2- (1- (benzenesulfonyl) piperidin-4-yl) -1H- benzimidazoles
I -3 2- (1- (3,4- dichloros benzenesulfonyl) piperidin-4-yl) -1H- benzimidazoles
I -4 3- (4- (1- (2- ethoxyethyl groups) -1H- benzimidazolyl-2 radicals-yl) piperidin-1-yl sulfonyl) cyanophenyl
I -5 2- (1- (furans -2- bases sulfonyl) piperidin-4-yl) -1H- benzimidazoles
I -6 1- (2- ethoxyethyl groups) -2- (1- (5- methylfuran -2- bases sulfonyl) piperidin-4-yl) -1H- benzo miaows Azoles
I -7 5- (4- (1H- benzimidazolyl-2 radicals-yl) piperidin-1-yl sulfonyl) furans -2- nitriles
I -8 1- (2- ethoxyethyl groups) -2- (1- (thiophene -2- bases sulfonyl) piperidin-4-yl) -1H- benzimidazoles
I -9 2- (1- (thiophene -2- bases sulfonyl) piperidin-4-yl) -1H-5- tolimidazoles
I -10 1- (2- ethoxyethyl groups) -2- (1- (5- methylthiophene -2- bases sulfonyl) piperidin-4-yl) -1H- benzos Imidazoles
Generalformulaⅰcompound pharmaceutically acceptable salt refers to：Compound and inorganic acid, organic acid are into salt.It is wherein preferred：Hydrochloric acid Salt, hydrobromate, hydriodate, sulfate, disulfate, phosphate, acetate, propionate, butyrate, lactate, first sulphur Hydrochlorate, tosilate, maleate, benzoate, succinate, tartrate, citrate, fumarate, ox sulphur Hydrochlorate etc..
The syntheti c route of type I compound is as follows：
X is O, S；R1、R2、R3As defined above
Using dichloromethane, chloroform, ethyl acetate, N,N-dimethylformamide, 1,4- dioxane or acetonitrile to be molten Agent, substituted 2- (piperidin-4-yl)-benzo [d] imidazoles is dissolved, in triethylamine, N, N- diisopropyl ethylenediamines, pyridine, carbon Under the catalysis of the acid binding agents such as sour potassium, sodium carbonate, sodium acid carbonate, sodium hydroxide or potassium hydroxide, -30~80 DEG C be added dropwise sulfonic acid chlorides with The mixed liquor of solvent, react and chemical compounds I is made.
Reaction is made various compounds or products therefrom is dissolved in into DMF, acetone, methanol, ethanol, isopropanol, ether, acetic acid Inorganic acid is added dropwise in ethyl ester or DMSO, pharmaceutically acceptable salt is made in organic acid.
Specifically products therefrom is dissolved in DMF, acetone, methanol, ethanol, isopropanol, ether or DMSO, hydrochloric acid second is added dropwise Hydrochloride is made to pH2 in ether.Or products therefrom is dissolved in DMF, acetone, methanol or ethanol, equimolar lactic acid is added, obtains its breast Hydrochlorate.
Such compound is effective for disease caused by treatment hyperglycaemia.Although the compound of the present invention can be without Any prepare is directly administered, but described various compounds preferably use in the form of a pharmaceutical preparation, and method of administration can be with right and wrong Enteral routes (such as vein, intramuscular delivery) and oral administration.
The pharmaceutical composition of the compounds of this invention prepares as follows：Using standard and conventional technique, make the compounds of this invention Combined with acceptable solid or liquid-carrier on galenic pharmacy, and be allowed to arbitrarily with acceptable adjuvant on galenic pharmacy and Excipient combines and is prepared into particulate or microballoon.Solid dosage forms includes tablet, discrete particles, capsule, sustained release tablets, sustained release pellet etc. Deng.Solid carrier can be at least one material, and it can serve as diluent, flavouring agent, solubilizer, lubricant, suspending agent, viscous Mixture, disintegrant and coating agent.Inert solid carrier includes magnesium phosphate, magnesium stearate, smoothers sugar, lactose, pectin, the third two Alcohol, polyoxyethylene sorbitan monoleate, dextrin, starch, gelatin, cellulose substances such as methylcellulose, microcrystalline cellulose, low melting point stone Wax, polyethylene glycol, mannitol, cocoa butter etc..Liquid dosage form includes solvent, suspension such as injection, pulvis etc..
The amount of the active component (the compounds of this invention) contained in pharmaceutical composition and unit dosage form can be according to patient The state of an illness, the situation of diagnosis be specifically applied, the amount or concentration of compound used are in a wider scope Regulation.Generally, the scope of reactive compound amount is 0.5~90% (weight) of composition, another preferable scope is 0.5~ 70%.
The compound or its pharmaceutically acceptable salt with structure shown in formula I of the present invention, has significantly at hypoglycemic aspect Inhibitory action.
Embodiment
With reference to embodiment, the present invention is described further, and embodiment is only explanatory, is in no way intended to it The scope limiting the invention in any way.Described compound is carried out through high performance liquid chromatography (HPLC), thin-layer chromatography (TLC) Detection.It can then use such as infrared spectrum (IR), nuclear magnetic resoance spectrum (1H NMR,13C NMR), mass spectrum (MS) etc. more enters one Step confirms its structure.
Embodiment 1：
2- (1- tosylpiperidin -4- bases) -1H- benzimidazoles (compound I-1)
Equipped with stirring, condenser, thermometer reaction bulb in add 2- (piperidin-4-yl) -1H- benzos [d] imidazoles (10.06g,
0.05mol), triethylamine (10.10g, 0.1mol) is added after being dissolved with 50ml dichloromethane, is stirred at -10 DEG C~5 DEG C Mix, dichloromethane (30ml) solution of paratoluensulfonyl chloride (11.44g, 0.06mol) is added dropwise, (flaggy is shown anti-low-temp reaction 3h Should be complete) after, distilled water washing reaction liquid (50ml × 3), organic layer anhydrous sodium sulfate drying, filtering, remove under reduced pressure organic Solvent, residue are separated with silica gel column chromatography, produce near-white solid I-1 (16.44g, yield 92.50%), purity 98.91% (HPLC).Rf=0.72 [single-point, solvent：V (petroleum ether):V (ethyl acetate)=1:3].ESI-HRMS:Calcd for C19H22N3O2S(M+H)356.1427,found 356.1431.
With reference to the method for embodiment 1, target compound I -2~I -10 can be made.
Embodiment 2：
The hydrochloric acid salt of chemical compounds I -1：I -1 near-white solid product 4.0g is taken, is dissolved in 11mL anhydrous isopropyl alcohols.Ice-water bath is cold But to 5 DEG C, it is 2 that 10.7% hydrochloric acid aqueous isopropanol, which is added dropwise, to pH, continues at stir about 1h under ice-water bath.Filtering, is obtained white solid Body.
Embodiment 3：
The one-tenth sulfate of chemical compounds I -2：I -2 white solid product 4.3g is taken, is dissolved in 30mL acetone.Ice-water bath is cooled to 5 DEG C, It is 3 that 9.8% sulfuric acid acetone soln, which is added dropwise, to pH, continues at stir about 1h under ice-water bath.Filtering, obtains white solid.
Embodiment 4：
The one-tenth lactate of chemical compounds I -5：I -5 white solid product 5.0g is taken, is dissolved in 20mL absolute methanols.After being heated to backflow Equimolar lactic acid is added, continues at stirred at reflux reaction about 1h.Reaction finishes, and stands 24h at room temperature.Separate out faint yellow knot Crystalline substance, filter, vacuum drying.
In order to which the pharmaceutical composition of the benzimidizole derivatives containing piperidines of the present invention is more fully explained, it is provided below down Series preparation embodiment, the embodiment are merely to illustrate, rather than for limiting the scope of the present invention.The preparation can use Any reactive compound and its salt in the compounds of this invention, preferably using the compound described in embodiment 1-4.
Embodiment 5：
Hard gelatin capsule is prepared with following compositions：
Preparation technology：Supplementary material is pre-dried, it is standby to cross 100 mesh sieves.After by recipe quantity, mentioned component is mixed, filling Enter in hard gelatin capsule.
Embodiment 6：
Tablet is prepared with following compositions：
Preparation technology：Supplementary material is pre-dried, it is standby to cross 100 mesh sieves.First the auxiliary material of recipe quantity is fully mixed.By original Material medicine is added in auxiliary material with incremental dilution method, and each added-time fully mixes 2-3 times, is ensured that medicine fully mixes with auxiliary material, is crossed 20 mesh Sieve, dries 2h in 50 DEG C of ventilated drying ovens, and dry particl crosses the arrangement of 16 mesh sieves, determines intermediates content, is well mixed, in tablet press machine Upper tabletting.
Embodiment 7：
The preparation of parenteral solution：
Preparation method：Take active component to be added in the water for injection for having dissolved sorbierite and propane diols, add medicinal basic Regulation pH value makes its dissolving to 4~8.Add activated carbon, stirring and adsorbing 30min, carbon removal, refined filtration, embedding, sterilizing.
Embodiment 8：
The preparation of injection freeze-dried powder：
The 100mg of chemical compounds I -5
Medicinal basic 0.1-7.0%
Mannitol 55-85%
Preparation method：Take active component to add water for injection, make its dissolving with medicinal basic regulation pH value to 4-8.Add Mannitol, autoclaving is carried out by the requirement of injection, adds activated carbon, using filtering with microporous membrane, filtrate is dispensed, and is adopted With freeze-drying, loose block is made, sealing, produces.
Embodiment 9：
External insulin-sensitizing activity test
By 3T3-L1 cell culture in the DMEM nutrient solutions containing 10%NBS, passage in every 3 days is once.Cell is placed in 24 holes In culture plate, with 0.5mmol/L IBMX and l μm of ol/L DEX and 1.0 μm of ol/L insulin processing 48h after covering with, add simultaneously The test-compound of various dose (0.01,0.1 and l μm of ol/L), continue culture to experiment and terminate.Cell is collected, uses colorimetric method The triglycerides and protein content in cell are determined, calculates the incrementss of intracellular triglyceride after administration.Positive control Group selects rosiglitazone.Blank control group is the nutrient solution containing 0.1% dimethyl sulfoxide (DMSO).Fat before target compound stimulates The Activity Results of fat cell differentiation lipoblast are shown in Table 1.
The target compound of table 1 stimulates the activity of PECTORAL LIMB SKELETON differentiation lipoblast
From can substantially suppress blood glucose rise with the pharmacological results of upper table 1, compound of the invention.

Claims (10)

1. compound or its pharmaceutically acceptable salt with structure shown in formula I：
Wherein：
R1For：Hydrogen, fluorine, chlorine, bromine, C1-C4Straight or branched alkyl；
R2For：Ethyoxyl alkyl；
R3For：(a)Wherein R4, R5It is at the same time or separately hydrogen, C1-C4 alkyl, halogen, nitro, cyano group, C1-C4 alkane Epoxide；
(b)Wherein X is O or S；R6, R7It is at the same time or separately hydrogen, C1-C4 alkyl, halogen, nitro, cyano group, C1-C4 alkane Epoxide.
2. there is the compound or its pharmaceutically acceptable salt of structure shown in formula I as claimed in claim 1：
Wherein：
R1For：Hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, the tert-butyl group；
R2For：Ethyoxyl alkyl；
R3For：(a)Wherein R4, R5It is at the same time or separately hydrogen, methyl, ethyl, propyl group, isopropyl, butyl, isobutyl Base, the tert-butyl group, fluorine, chlorine, bromine, nitro, cyano group, methoxyl group, ethyoxyl, propoxyl group, butoxy, isopropoxy, tert-butoxy；
(b)Wherein X is O or S；R6, R7It is at the same time or separately hydrogen, methyl, ethyl, propyl group, isopropyl, butyl, isobutyl Base, the tert-butyl group, fluorine, chlorine, bromine, nitro, cyano group, methoxyl group, ethyoxyl, propoxyl group, isopropoxy, butoxy, tert-butoxy.
3. the compound of following structure or its pharmaceutically acceptable salt：
Ⅰ-2
Ⅰ-4
Ⅰ-5
Ⅰ-6
Ⅰ-7
Ⅰ-8
Ⅰ-9
Ⅰ-10
4. having the compound or its pharmaceutically acceptable salt of structure shown in formula I as claimed in claim 1 or 2, it pharmaceutically may be used The salt of receiving is：Compound of formula I and inorganic acid, organic acid are into salt.
5. having the compound or its pharmaceutically acceptable salt of structure shown in formula I as claimed in claim 4, its is pharmaceutically acceptable Salt be：Hydrochloride, hydrobromate, hydriodate, sulfate, disulfate, phosphate, acetate, propionate, butyrate, Lactate, mesylate, tosilate, maleate, benzoate, succinate, tartrate, citrate, richness Horse hydrochlorate, taurate.
6. the preparation method of the compound with structure shown in formula I as claimed in claim 1 or 2, it is characterised in that：Substituted benzo For glyoxaline compound with sulfonic acid chloride class compound in the presence of acid binding agent, chemical combination is made in -30~80 DEG C of reactions in organic solvent Thing I, wherein each substituent is as claimed in claim 1 or 2；
7. the preparation method of the compound with structure shown in formula I as claimed in claim 6, it is characterised in that：Described acid binding agent It is selected from：Triethylamine, N, N- diisopropylethylamine, pyridine, potassium carbonate, sodium carbonate, sodium acid carbonate, sodium hydroxide or potassium hydroxide.
8. the preparation method of the compound with structure shown in formula I as claimed in claim 6, it is characterised in that：Described is organic molten Agent is selected from：Ethyl acetate, dichloromethane, chloroform, toluene, DMF, DMSO or acetonitrile.
9. a kind of pharmaceutical composition, it has structure shown in formula I comprising therapeutically effective amount as described in any one of claim 1~2 Compound or its pharmaceutically acceptable salt and one or more pharmaceutical carriers.
10. if the compound of any one of claim 1~2 with structure shown in formula I or its pharmaceutically acceptable salt are for making Application in terms of hypoglycemic medicament of making preparation for dropping.
CN201510137918.5A 2015-03-26 2015-03-26 Benzimidizole derivatives containing piperidines and its production and use Active CN104860919B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510137918.5A CN104860919B (en) 2015-03-26 2015-03-26 Benzimidizole derivatives containing piperidines and its production and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510137918.5A CN104860919B (en) 2015-03-26 2015-03-26 Benzimidizole derivatives containing piperidines and its production and use

Publications (2)

Publication Number Publication Date
CN104860919A CN104860919A (en) 2015-08-26
CN104860919B true CN104860919B (en) 2017-11-10

Family

ID=53907152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510137918.5A Active CN104860919B (en) 2015-03-26 2015-03-26 Benzimidizole derivatives containing piperidines and its production and use

Country Status (1)

Country Link
CN (1) CN104860919B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289840A (en) * 2015-11-30 2018-07-17 葛兰素史密斯克莱知识产权（第2号）有限公司 Preparation for being injected intravenously Danirixin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9612434A (en) * 1995-12-28 1999-12-28 Fujiwasa Pharmaceutical Co Ltd Benzimidazole derivatives
JPWO2002068407A1 (en) * 2001-02-28 2004-06-24 山之内製薬株式会社 Benzimidazole compounds
AR045496A1 (en) * 2003-08-29 2005-11-02 Schering Corp ANALOLGES OF BENZIMIDAZOLPIPERIDINAS 2- SUBSTIZED AS ANTAGONISTS OF HORMONE RECEPTORS CONCENTRATING SELECTIVE MELANINE FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
CN101374813A (en) * 2004-04-07 2009-02-25 凯利普西斯公司 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders
US20100144591A1 (en) * 2007-03-02 2010-06-10 Schering Corporation Benzimidazole derivatives and methods of use thereof
JP2012529448A (en) * 2009-06-08 2012-11-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Substituted benzimidazoles, benzothiazoles and benzoxazoles
WO2012170867A1 (en) * 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289840A (en) * 2015-11-30 2018-07-17 葛兰素史密斯克莱知识产权（第2号）有限公司 Preparation for being injected intravenously Danirixin

Also Published As

Publication number Publication date
CN104860919A (en) 2015-08-26

Similar Documents

Publication Publication Date Title
CN104918936B (en) The pyridine-2-carboxamide compound being substituted as apoptosis signal regulating kinase inhibitor
CN103044395B (en) Desloratadine-containing amino acid derivative as well as preparation method and application thereof
CN110072861A (en) For treating the disubstituted pyrazole class compound of disease
CN104860919B (en) Benzimidizole derivatives containing piperidines and its production and use
CN106317068A (en) C, O-spiro aryl glycoside compound and preparation and application thereof
CN103864765B (en) Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use
CN107556276B (en) C- triaryl glucoside compounds and its preparation method and application
CN101974016A (en) Amide compound and preparation method and applications thereof
CN102838651B (en) Oleanolic acid derivatives, and preparation method and application thereof
CN104926804B (en) One kind has compound, the preparation method and use of antitumor action
CN111039880B (en) Application of miconazole and derivative thereof as TGR5 agonist
CN105111151B (en) Aminopyridine derivative as PPAR- gamma modulators
CN103012314B (en) Sulfonamide compound and preparation method as well as application thereof
CN104292211A (en) Desloratadine nitric oxide donor, and preparation method and application thereof
CN107445979A (en) 6 methylthiazols and the carboxamides derivatives of triazole 5 and application
CN102617491A (en) 3-oxo-3,4-dihydro-2-pyrazinecarboxamide derivative, medicinal composition thereof and preparation method and application of 3-oxo-3,4-dihydro-2-pyrazinecarboxamide derivative
CN109280067B (en) Diosmin derivative, preparation method and medical application thereof
CN107235994B (en) Simultaneously [3,2-a] pyrimidine -3- acetamide derivative and the application of 5,7- diphenyl -5H- thiazole
CN103804367B (en) Benzazepine derivant, Preparation Method And The Use
CN104710355B (en) The preparation method and purposes of diphenyl thiourea compounds and its salt of one class containing niacinamide building block
CN103626722A (en) Hypoglycemic compound of nitric oxide donor type, preparation method and purpose thereof
CN103880793B (en) Containing furan imine compound and its production and use
CN102276626B (en) Isoxazole-containing compound
CN107501299A (en) The simultaneously carboxamides derivatives of [3,2 a] pyrimidine 2 and the application of 5,7 diphenyl 5H thiazoles
CN102276625B (en) Thiadiazole derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210804

Address after: 300301 No. 308, Huiren Road, Binhai Science Park, Binhai high tech Zone, Tianjin Binhai New Area, Tianjin

Patentee after: Tianjin Tiancheng new drug evaluation Co.,Ltd.

Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308

Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd.